Treatment Responses in Hodgkin and Non-Hodgkin Lymphoma Through the Lens of FDG PET/CT Imaging

Hodgkin and non-Hodgkin lymphomas are prevalent hematological malignancies necessitating precise treatment response assessment to inform subsequent therapeutic decisions and prognosis prediction. FDG PET/CT emerging as a reliable technique offering high sensitivity and specificity in lesion detection and response assessment. This study aimed to compare treatment responses in Hodgkin and non-Hodgkin lymphoma patients using FDG PET/CT. The retrospective analysis involved 152 patients with confirmed lymphoma subtypes, employing quantitative parameters like standardized uptake value (SUVmax) and metabolic tumor volume (MTV) to assess response. Findings revealed a higher prevalence of Hodgkin’s lymphoma among females, more follow-up examinations, and similar complete metabolic responses for both subtypes, but Hodgkin’s lymphoma exhibited higher mild/high partial responses and non-Hodgkin lymphoma had lower progressive metabolic disease. Follow-up intervals differed, with Hodgkin’s lymphoma patients scheduled for assessments every 2–3 months after the initial visit and non-Hodgkin lymphoma patients every 3–6 months post-treatment. Notably, Hodgkin’s lymphoma displayed greater treatment responsiveness in specific regions, while non-Hodgkin lymphoma exhibited lower recurrence rates. Optimal follow-up protocols were recommended accordingly for each subtype.